Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Consensus Price Target from Analysts

Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $31.00.

MPLT has been the topic of several recent analyst reports. Wall Street Zen raised Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Morgan Stanley began coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued an “overweight” rating and a $34.00 price objective for the company. Leerink Partners started coverage on Maplight Therapeutics in a report on Friday, November 21st. They set an “outperform” rating and a $30.00 target price on the stock. Weiss Ratings began coverage on Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Finally, Jefferies Financial Group started coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 price target on the stock.

Maplight Therapeutics Stock Up 0.1%

Shares of Maplight Therapeutics stock opened at $18.02 on Monday. Maplight Therapeutics has a 12-month low of $12.24 and a 12-month high of $21.55. The firm has a market cap of $817.62 million and a PE ratio of -0.48. The stock’s 50-day moving average price is $17.64.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Insider Transactions at Maplight Therapeutics

In other news, Director Robert C. Malenka sold 21,262 shares of the stock in a transaction that occurred on Thursday, January 29th. The shares were sold at an average price of $18.55, for a total transaction of $394,410.10. Following the sale, the director directly owned 371,885 shares of the company’s stock, valued at $6,898,466.75. This represents a 5.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director George Pavlov purchased 10,658 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was bought at an average cost of $17.48 per share, with a total value of $186,301.84. Following the acquisition, the director owned 10,658 shares of the company’s stock, valued at $186,301.84. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 39,124 shares of company stock worth $693,846 and have sold 74,612 shares worth $1,368,065.

Hedge Funds Weigh In On Maplight Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. bought a new stake in Maplight Therapeutics during the 4th quarter worth about $56,672,000. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Maplight Therapeutics during the 4th quarter worth approximately $49,154,000. Goldman Sachs Group Inc. bought a new stake in shares of Maplight Therapeutics during the fourth quarter worth approximately $34,026,000. Nan Fung Group Holdings Ltd acquired a new position in Maplight Therapeutics in the fourth quarter valued at approximately $17,060,000. Finally, 5AM Venture Management LLC bought a new position in Maplight Therapeutics in the fourth quarter valued at approximately $16,687,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.